157 related articles for article (PubMed ID: 3144532)
1. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
Nakashima M; Kanamaru M; Uematsu T; Takiguchi A; Mizuno A; Itaya T; Kawahara F; Ooie T; Saito S; Uchida H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():133-44. PubMed ID: 3144532
[TBL] [Abstract][Full Text] [Related]
2. Single and multiple dose pharmacokinetics of fleroxacin.
Weidekamm E; Portmann R; Partos C; Dell D
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():145-54. PubMed ID: 3144533
[TBL] [Abstract][Full Text] [Related]
3. The metabolism and pharmacokinetics of fleroxacin in healthy subjects.
Griggs DJ; Wise R; Kirkpatrick B; Ashby JP
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():191-4. PubMed ID: 3144537
[TBL] [Abstract][Full Text] [Related]
4. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.
Taburet AM; Devillers A; Thomare P; Fillastre JP; Veyssier P; Singlas E
Clin Pharmacokinet; 1990 Jul; 19(1):80-8. PubMed ID: 2116257
[TBL] [Abstract][Full Text] [Related]
5. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
Singlas E; Leroy A; Sultan E; Godin M; Moulin B; Taburet AM; Dhib M; Fillastre JP
Clin Pharmacokinet; 1990 Jul; 19(1):67-79. PubMed ID: 2116256
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.
Hayton WL; Vlahov V; Bacracheva N; Viachki I; Portmann R; Muirhead G; Stoeckel K; Weidekamm E
Antimicrob Agents Chemother; 1990 Dec; 34(12):2375-80. PubMed ID: 2128442
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
Sorgel F; Metz R; Naber K; Seelmann R; Muth P
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():155-67. PubMed ID: 3144534
[TBL] [Abstract][Full Text] [Related]
8. Comparative oral pharmacokinetics of fleroxacin and pefloxacin.
De Lepeleire I; Van Hecken A; Verbesselt R; Tjandra-Maga TB; De Schepper PJ
J Antimicrob Chemother; 1988 Aug; 22(2):197-202. PubMed ID: 3141343
[TBL] [Abstract][Full Text] [Related]
9. Altered disposition of fleroxacin in patients with cystic fibrosis.
Mimeault J; Vallée F; Seelmann R; Sörgel F; Ruel M; LeBel M
Clin Pharmacol Ther; 1990 May; 47(5):618-28. PubMed ID: 2111750
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of fleroxacin in man.
Sörgel F; Seelmann R; Naber K; Metz R; Muth P
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():169-78. PubMed ID: 3144535
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.
Chukwuani CM; Coker HA; Oduola AM; Sowunmi A; Ifudu ND
Biol Pharm Bull; 2000 Aug; 23(8):968-72. PubMed ID: 10963305
[TBL] [Abstract][Full Text] [Related]
12. Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers.
Shah PM; Sammann A; Schäfer V; Seczendi M; Knothe H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():209-13. PubMed ID: 3144539
[TBL] [Abstract][Full Text] [Related]
13. Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.
Parent M; St-Laurent M; LeBel M
Antimicrob Agents Chemother; 1990 Jun; 34(6):1249-53. PubMed ID: 2118328
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
Begg EJ; Robson RA; Saunders DA; Graham GG; Buttimore RC; Neill AM; Town GI
Br J Clin Pharmacol; 2000 Jan; 49(1):32-8. PubMed ID: 10606835
[TBL] [Abstract][Full Text] [Related]
15. Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.
Heim-Duthoy K; Peltier G; Awni W
Antimicrob Agents Chemother; 1990 May; 34(5):922-3. PubMed ID: 2113797
[TBL] [Abstract][Full Text] [Related]
16. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
Jiao Y; Kim TH; Tao X; Kinzig M; Landersdorfer CB; Drescher SK; Sutaria DS; Moya B; Holzgrabe U; Sörgel F; Bulitta JB
Eur J Pharm Sci; 2018 Oct; 123():416-428. PubMed ID: 30076955
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.
Stuck AE; Frey FJ; Heizmann P; Brandt R; Weidekamm E
Antimicrob Agents Chemother; 1989 Mar; 33(3):373-81. PubMed ID: 2499248
[TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
Naber KG; Sörgel F; Kees F; Schumacher H; Metz R; Grobecker H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():199-207. PubMed ID: 2462556
[TBL] [Abstract][Full Text] [Related]
19. Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers.
Chukwuani CM; Coker HA; Oduola AM; Ifudu ND; Sowunmi A
Chemotherapy; 1998; 44(6):369-76. PubMed ID: 9755295
[TBL] [Abstract][Full Text] [Related]
20. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.
Nakashima M; Uematsu T; Kosuge K; Kusajima H; Ooie T; Masuda Y; Ishida R; Uchida H
Antimicrob Agents Chemother; 1995 Dec; 39(12):2635-40. PubMed ID: 8592993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
